|
|
4 Manhattanville Road
Purchase, NY 10577 USA
phone:914-701-4500
fax:914-696-0860
|
|
| Symbol |
NXXI |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.nutrition21.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceuticals targeting the diabetes marketplace. |
|
| Management |
| Michael A. Zeher; Dean DiMaria; Alan J. Kirschbaum; James Komorowski, M.S; William J. Levi |
| |
|
|
|
|
|
|
|
| Keywords |
| Diabetes, blood sugar, diabetic, metabolic, insulin, insulin, obesity, metabolic syndrome, cardiovascular disease, depression. |
|
|
|
| Description |
|
Nutrition 21 uses patented technology, pharmaceutical research and strategic marketing and distribution partnerships to build its position in therapeutic markets. The Company is targeting the diabetes marketplace and related health markets where poor insulin function is a metabolic risk factor. These include obesity, metabolic syndrome, cardiovascular disease and depression. |
|
| Products / Services |
The Company holds 24 U.S. patents for chromium compounds, their uses and Chromax chromium picolinate, a unique form of chromium with superior bioactivity.
|
|
| Technology / Differentiation |
| Poor insulin function and glucose control are strong bio-markers for diabetes. Chromium is a trace mineral essential for healthy insulin function and blood sugar levels. Twelve published clinical studies involving over 1500 subjects demonstrate that supplemental use of Chromax chromium picolinate, at 200 to 1000 mcg has demonstrated an ability to improve glycemic control in people with or at risk for diabetes. |
|
| Market / Customers |
Diabetes, insulin management
|
|
| Strategy |
The Company is focused on developing products that are marketed under the Dietary Supplement Health and Education Act (DSHEA) regulatory pathway.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
